Evogene Ltd.
P.O. Box 2100
Rehovot
76121
Tel: 972-8-9311900
Fax: 972-8-9466724
Website: http://www.evogene.com/
Email: info@evogene.com
181 articles about Evogene Ltd.
-
Evogene Reports Fourth Quarter and Full Year 2023 Financial Results
3/7/2024
Evogene Ltd. today announced its financial results for the fourth quarter and full-year period ending December 31, 2023.
-
Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024
2/26/2024
Evogene Ltd announced today that it will release its financial results for the third quarter of 2023 on Thursday, March 7th, 2024.
-
Evogene Reports Third Quarter 2023 Financial Results
11/15/2023
Evogene Ltd today announced its financial results for the third quarter period ended September 30, 2023.
-
Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023
11/2/2023
Evogene Ltd. announced that it will release its financial results for the third quarter of 2023, on Wednesday, November 15, 2023.
-
Evogene Reports Second Quarter 2023 Financial Results
8/17/2023
Evogene Ltd. today announced its financial results for the second quarter period ended June 30, 2023.
-
Evogene Schedules Second Quarter 2023 Financial Results Release & Conference Call for August 17, 2023
8/1/2023
Evogene Ltd announced today that it will release its financial results for the second quarter of 2023, on Thursday, August 17, 2023.
-
Biomica Announces Interim Positive Results from Pre-Clinical Studies in its Irritable Bowel Syndrome (IBS) Program
7/19/2023
Biomica Ltd. reported today interim positive results from pre-clinical studies in its IBS program.
-
Evogene Announces Pricing of US$8,500,000 Registered Direct Offering
7/17/2023
Evogene Ltd today announced it has entered into securities purchase agreements with institutional investors (including SilverArc Capital Management, Altium Capital Management, LP and CVI Investments, Inc.) for the purchase and sale of 8,500,000 ordinary shares in a registered direct offering at a purchase price of $1.00 per ordinary share.
-
Evogene Reports First Quarter 2023 Financial Results
5/18/2023
Evogene Ltd. today announced its financial results for the first quarter period ending March 31, 2023.
-
Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance
5/9/2023
The Ag-Seed Division of Evogene Ltd. has announced that it has been granted a prestigious EU Horizon grant of €1.2 million, to support the creation of oil-seed crops that have high carbon-dioxide assimilation and enhanced drought tolerance.
-
Evogene Schedules First Quarter 2023 Financial Results Release & Conference Call for May 18, 2023
5/4/2023
Evogene Ltd.announced today that it will release its financial results for the first quarter of 2023, on Thursday, May 18, 2023.
-
Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital
4/27/2023
Biomica Ltd. today announced that it has closed a financing round of $20 million.
-
Evogene Announces Filing of Annual Report on Form 20-F
3/30/2023
Evogene Ltd. announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 with the Securities and Exchange Commission.
-
Evogene Reports Fourth Quarter and Full Year 2022 Financial Results
3/9/2023
Evogene Ltd. today announced its financial results for the fourth quarter and full year period ending December 31, 2022.
-
Lavie Bio to Host a Round Table Discussion and is a Sponsor at World Agri-Tech Conference in San Francisco
3/6/2023
Lavie Bio Ltd. today announced in that its management will be sponsoring and participating at the World Agri-Tech Conference in San Francisco, taking place between March 14-15, 2023.
-
Evogene to Attend the Annual ROTH Investor Conference in California on March 13, 2023
3/1/2023
Evogene Ltd. today announced that it will attend and meeting with investors at the 35th Annual ROTH Conference being held in Dana Point, California on March 13-14, 2023.
-
Evogene Schedules Fourth Quarter and Full Year 2022 Financial Results Release & Conference Call for March 9, 2023
2/27/2023
Evogene Ltd. announced today that it will release its financial results for the fourth quarter and full year 2022 on Thursday, March 9, 2023.
-
Biomica CEO to Participate in Panel Discussion at 7th European Annual Microbiome Movement
1/24/2023
Biomica Ltd. today announced its CEO and VP R&D will both be participating in 7th Annual Microbiome Movement Drug Development Europe, taking place in London, UK, between January 31 and February 2, 2023.
-
Biomica CEO to Attend the JP Morgan Healthcare Week in San Francisco between January 9-11, 2023
12/28/2022
Biomica Ltd. and a subsidiary of Evogene Ltd., announced it will be in attendance at the Healthcare Week taking place together with the J.P. Morgan Healthcare Conference in San Francisco.
-
Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics
12/21/2022
Biomica Ltd. today announced the signing of a definitive agreement for a $20 million financing round.